世界の白血病治療薬市場は、2023年に約160億1,000万米ドルと評価され、2024年から2032年の予測期間を通じて6.80%という堅調な年平均成長率（CAGR）で拡大すると予想されています。白血病は、小児と成人の両方に影響を与える最も悪性度の高いがんの一つであり、より効果的で個別化された治療法の開発に向けて世界中で熱烈な反応が起こっています。白血球の制御不能な増殖を特徴とするこの疾患は、標的療法、免疫療法、そして精密腫瘍学における画期的な進歩によって克服されています。認知度の高まり、早期診断能力、そして個別化医療の台頭により、治療成功率は大幅に向上し、白血病治療のあり方は大きく変化しました。
高齢化、環境要因、遺伝的素因によって引き起こされた白血病発症率の急増は、製薬業界に行動を促しました。継続的な研究開発活動により、CAR-T細胞療法、チロシンキナーゼ阻害薬（TKI）、二重特異性抗体といった次世代治療薬の開発が可能になり、特に従来の化学療法レジメンに抵抗性を示す患者への治療が期待されています。白血病の種類の中でも、慢性リンパ性白血病（CLL）と急性骨髄性白血病（AML）は依然として最も有病率が高く、治療革新の大きな部分を担っています。さらに、服薬コンプライアンスの向上と入院期間の短縮を背景に、経口薬の需要が高まっており、医療システム全体の治療パラダイムを変革しつつあります。
有望な開発が見られる一方で、市場はいくつかの重大な課題に直面しています。生物学的製剤に伴う高額な費用と低所得地域におけるアクセスの制限が、公平な治療配分を阻害しています。さらに、治療耐性、有害な副作用、そして白血病のサブタイプの多様性は、医薬品の設計と臨床戦略の継続的な進化を必要としています。しかしながら、こうした複雑さは、製薬企業が無増悪生存期間と全体的な患者アウトカムの両方を改善する可能性を秘めた、革新的なマルチモーダル治療法や併用療法への投資を促すきっかけとなっています。
地域別では、先進的な医療インフラ、包括的な保険償還枠組み、そしてFDAによるオーファンドラッグへの強力な支援に支えられ、北アメリカが最大の市場シェアを占めています。希少がんへの公的資金提供やホライズン・ヨーロッパなどの取り組みが牽引するヨーロッパも、僅差で追随しています。一方、アジア太平洋地域は、がん意識の高まり、政府による健康キャンペーン、そして中国、インド、日本といった国々における臨床試験へのアクセス拡大に後押しされ、最も急速な成長が見込まれています。こうした動向と多国籍製薬企業の存在感の高まりは、この地域が白血病治療における主要な成長フロンティアへと急速に成長していくことを示唆しています。
目次
Table of Contents
Chapter 1. Global Leukemia Therapeutics Market Executive Summary
1.1. Global Leukemia Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Treatment Type
1.3.3. By Mode of Administration
1.3.4. By Molecule Type
1.3.5. By Gender
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Leukemia Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Leukemia Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Rising Incidence of Leukemia and Aging Populations
3.1.2. Breakthroughs in Targeted and Immuno-Oncology Therapies
3.1.3. Expansion of Personalized Medicine and Early Diagnostics
3.2. Market Challenges
3.2.1. High Cost of Innovative Biologic Treatments
3.2.2. Therapeutic Resistance and Adverse Effects
3.2.3. Unequal Access in Emerging and Low-Income Regions
3.3. Market Opportunities
3.3.1. Growth of Oral and Outpatient Treatment Modalities
3.3.2. Development of Combination and Multi-Modal Regimens
3.3.3. Expansion into Fast-Growing Asia Pacific and Latin America
Chapter 4. Global Leukemia Therapeutics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Leukemia Therapeutics Market Size & Forecasts by Type 2022-2032
5.1. Segment Dashboard
5.2. Global Leukemia Therapeutics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Chronic Lymphocytic Leukemia (CLL)
5.2.2. Acute Lymphocytic Leukemia (ALL)
5.2.3. Chronic Myeloid Leukemia (CML)
5.2.4. Acute Myeloid Leukemia (AML)
Chapter 6. Global Leukemia Therapeutics Market Size & Forecasts by Treatment Type 2022-2032
6.1. Segment Dashboard
6.2. Global Leukemia Therapeutics Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Chemotherapy & Targeted Drugs
6.2.1.1. CLL
6.2.1.2. ALL
6.2.1.3. CML
6.2.1.4. AML
Chapter 7. Global Leukemia Therapeutics Market Size & Forecasts by Mode of Administration 2022-2032
7.1. Segment Dashboard
7.2. Global Leukemia Therapeutics Market: Mode of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Global Leukemia Therapeutics Market Size & Forecasts by Molecule Type 2022-2032
8.1. Segment Dashboard
8.2. Global Leukemia Therapeutics Market: Molecule Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Small Molecules
8.2.2. Biologics
Chapter 9. Global Leukemia Therapeutics Market Size & Forecasts by Gender 2022-2032
9.1. Segment Dashboard
9.2. Global Leukemia Therapeutics Market: Gender Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Male
9.2.2. Female
Chapter 10. Global Leukemia Therapeutics Market Size & Forecasts by Region 2022-2032
10.1. North America Leukemia Therapeutics Market
10.1.1. U.S. Leukemia Therapeutics Market
10.1.1.1. Type breakdown size & forecasts, 2022-2032
10.1.1.2. Treatment Type breakdown size & forecasts, 2022-2032
10.1.2. Canada Leukemia Therapeutics Market
10.2. Europe Leukemia Therapeutics Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe Market
10.3. Asia-Pacific Leukemia Therapeutics Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia-Pacific Market
10.4. Latin America Leukemia Therapeutics Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.4.3. Rest of Latin America Market
10.5. Middle East & Africa Leukemia Therapeutics Market
10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Novartis AG
11.1.2. Pfizer Inc.
11.1.3. Bristol-Myers Squibb Company
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Novartis AG
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Pfizer Inc.
11.3.3. Bristol-Myers Squibb Company
11.3.4. F. Hoffmann-La Roche Ltd
11.3.5. AbbVie Inc.
11.3.6. AstraZeneca plc
11.3.7. Amgen Inc.
11.3.8. Johnson & Johnson
11.3.9. Gilead Sciences, Inc.
11.3.10. GlaxoSmithKline plc
11.3.11. Takeda Pharmaceutical Company Limited
11.3.12. BeiGene Ltd
11.3.13. Jazz Pharmaceuticals plc
11.3.14. Eli Lilly and Company
11.3.15. Sanofi S.A.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
List of Tables
TABLE 1. Global Leukemia Therapeutics market, report scope
TABLE 2. Global market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 4. Global market estimates & forecasts by Treatment Type 2022-2032 (USD Billion)
TABLE 5. Global market estimates & forecasts by Mode of Administration 2022-2032 (USD Billion)
TABLE 6. Global market estimates & forecasts by Molecule Type 2022-2032 (USD Billion)
TABLE 7. Global market estimates & forecasts by Gender 2022-2032 (USD Billion)
TABLE 8. Global market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. U.S. market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. U.S. market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 12. Canada market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Canada market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 14. Europe market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. Europe market estimates & forecasts by country 2022-2032 (USD Billion)
TABLE 16. Asia-Pacific market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 17. Latin America market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 18. Middle East & Africa market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Global market by competitive landscape, 2023 (Market Share %)
TABLE 20. Key players financial metrics comparison, 2022 & 2023
List of Figures
FIG 1. Global Leukemia Therapeutics market, research methodology
FIG 2. Global market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global market, key trends 2023
FIG 5. Global market, growth prospects 2022-2032
FIG 6. Global market, Porter’s 5 Force model
FIG 7. Global market, PESTEL analysis
FIG 8. Global market, value chain analysis
FIG 9. Global market by Type, 2022 & 2032 (USD Billion)
FIG 10. Global market by Treatment Type, 2022 & 2032 (USD Billion)
FIG 11. Global market by Mode of Administration, 2022 & 2032 (USD Billion)
FIG 12. Global market by Molecule Type, 2022 & 2032 (USD Billion)
FIG 13. Global market by Gender, 2022 & 2032 (USD Billion)
FIG 14. Global market, regional snapshot 2022-2032
FIG 15. North America market 2022-2032 (USD Billion)
FIG 16. Europe market 2022-2032 (USD Billion)
FIG 17. Asia-Pacific market 2022-2032 (USD Billion)
FIG 18. Latin America market 2022-2032 (USD Billion)
FIG 19. Middle East & Africa market 2022-2032 (USD Billion)
FIG 20. Global market, company market share analysis (2023)
